Department of Cardiology, Hospital Universitari i Politècnic La Fe, Avenida Fernando Abril Martorell 116, Valencia, Spain.
Department of Cardiology, MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC 20010, United States.
Curr Pharm Des. 2024;30(8):565-577. doi: 10.2174/0113816128284131240209113009.
Heart Failure (HF) remains a global health challenge, marked by its widespread prevalence and substantial resource utilization. Although the prognosis has improved in recent decades due to the treatments implemented, it continues to generate high morbidity and mortality in the medium to long term. Interventional cardiology has emerged as a crucial player in HF management, offering a diverse array of percutaneous treatments for both acute and chronic HF. This article aimed to provide a comprehensive review of the role of percutaneous interventions in HF patients, with a primary focus on key features, clinical effectiveness, and safety outcomes. Despite the growing utilization of these interventions, there remain critical gaps in the existing body of evidence. Consequently, the need for high-quality randomized clinical trials and extensive international registries is emphasized to shed light on the specific patient populations and clinical scenarios that stand to benefit most from these innovative devices.
心力衰竭（HF）仍然是一个全球性的健康挑战，其广泛的患病率和大量的资源利用使其显得尤为突出。尽管由于实施了治疗，近几十年来其预后有所改善，但从中长期来看，它仍然导致了高发病率和死亡率。介入心脏病学在 HF 管理中发挥了关键作用，为急性和慢性 HF 提供了多种经皮治疗方法。本文旨在全面回顾经皮介入在 HF 患者中的作用，主要关注其关键特征、临床效果和安全性结果。尽管这些介入的应用日益增多，但现有证据中仍存在关键空白。因此，强调需要高质量的随机临床试验和广泛的国际登记处，以阐明从这些创新设备中受益最大的特定患者人群和临床情况。
